01—Abstract
Summary
Summary of the 10-Q filed July 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Leidos Holdings, Inc. reported revenues of $4.13 billiona for the three months ended June 28, 2024, up from $3.84 billion a year earlier, and $8.11 billion for the six months, compared with $7.54 billion.
Operating income rose to $475 millionb for the quarter from $331 million, and to $890 million for the six months from $596 million. Net income attributable to Leidos common stockholders was $322 million for the quarter ($2.37 diluted EPS) versus $207 million ($1.50 diluted EPS) a year earlier. The filing notes that results include $39 million in write-downs on programs within the UK operations related to cost increases and schedule delays, and that the Commercial & International segment posted an operating loss of $11 million for the quarter.
Bookings and backlog were strong. Net bookings were an estimated $4.0 billionc for the quarter and $7.7 billion for the six months, compared with $2.9 billion and $5.9 billion a year earlier. Total backlog was $36.5 billion at June 28, 2024, versus $34.2 billion at June 30, 2023.
Net cash provided by operating activities was $437 milliond for the six months, up from $66 million, and cash and cash equivalents stood at $823 million. Total debt was $4.7 billion, and the company repurchased $250 million of common stock in the six months while paying $104 million in dividends. The filing also discloses ongoing government matters.
Leidos is conducting an internal investigation into international operations that may have violated the U.S. Foreign Corrupt Practices Act, has self-reported to the Department of Justice and the SEC, and is cooperating with both agencies. It also received a Department of Justice Antitrust Division grand jury subpoena in August 2022 related to three U.S. Government procurements, and states it cannot currently estimate any resulting fines or penalties.
02—Key points
Key Highlights
- Revenues rose 7.7% to $4.13 billion for the quarter and 7.6% to $8.11 billion for the six months, with growth in Health & Civil and Defense Systems.
- Operating income for the quarter was $475 million, up from $331 million, and operating margin was 11.5% versus 8.6%.
- Health & Civil operating income more than doubled to $307 million for the quarter, with operating margin of 24.3% versus 13.0%.
- Commercial & International posted a $11 million operating loss for the quarter, reflecting $39 million in UK program write-downs.
- Net bookings were $7.7 billion for the six months, and total backlog was $36.5 billion at June 28, 2024, up from $34.2 billion a year earlier.
- Diluted EPS for the quarter was $2.37, compared with $1.50 a year earlier.
- The company repurchased $250 million of common stock in the six months and paid $104 million in dividends, while total debt remained at $4.7 billion.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Leidos Holdings kept $0.08.
- Revenue$4.11B100.0%
- Cost of revenue−$3.43B83.4%
- Gross profit$680.0M16.6%
- Operating costs−$205.0M5.0%
- Operating income$475.0M11.6%
- Interest, other & tax−$153.0M3.7%
- Net income$322.0M7.8%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 30, 2024Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $4.11B$3.81B | +7.7% |
| Cost of Revenue | $3.43B$3.27B | +4.8% |
| Gross Profit | $680.00M$542.00M | +25.5% |
| SG&A Expenses | $231.00M$237.00M | −2.5% |
| Operating Income | $475.00M$331.00M | +43.5% |
| Net Income | $322.00M$207.00M | +55.6% |
| EPS (Basic) | $2.39$1.51 | +58.3% |
| EPS (Diluted) | $2.37$1.50 | +58.0% |
| Shares Outstanding (Basic) | 135.00M137.00M | −1.5% |
| Shares Outstanding (Diluted) | 136.00M138.00M | −1.4% |
05—Questions
Frequently Asked Questions
What drove the improvement in operating income this quarter?
Operating income rose to $475 million from $331 million, primarily driven by Health & Civil, where operating income increased to $307 million from $134 million on higher managed health services volumes, favorable business mix and write-ups on certain programs. National Security and Digital and Defense Systems also improved.
Are there material legal or regulatory risks disclosed?
Yes. The company is conducting an internal investigation into international operations that may have violated the U.S. Foreign Corrupt Practices Act and has self-reported to the Department of Justice and the SEC. It also received a grand jury subpoena from the DOJ Antitrust Division in August 2022 concerning three U.S. Government procurements, and states it cannot currently determine or estimate potential fines or penalties.
What is the company's liquidity position?
Leidos had $823 million in cash and cash equivalents at June 28, 2024, and an undrawn $1 billion revolving credit facility. Operating cash flow for the six months was $437 million, up from $66 million, and the company was in compliance with all debt covenants.
What are the UK write-downs and how large are they?
The filing discloses $39 million in write-downs for the three months and $40 million for the six months ended June 28, 2024, on programs within UK operations related to cost increases and schedule delays. These write-downs contributed to the Commercial & International segment's operating loss for the quarter.
How did the company deploy capital in the period?
Leidos repurchased $250 million of common stock in the six months ended June 28, 2024, including $100 million in the quarter, and paid $104 million in dividends. Debt was essentially unchanged at $4.7 billion.
06—Continue